A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

NCT02479412 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma
Efficacy
Safety

Interventions

DRUG: 800 μg AZD7594 once daily
DRUG: 250 µg AZD7594 once daily
DRUG: 58 µg AZD7594 once daily
DRUG: Placebo once daily
DRUG: Salbutamol

Sponsor

AstraZeneca